Physician profile
Luis A Acaba
NPI 1225031396
$19,133.31
in general payments reported to CMS, 2019-2025
53 companies · $4,325 in 2025
The $4,325 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $1,684 · 2021: $1,996 · 2022: $3,602 · 2023: $3,729 · 2024: $3,468 · 2025: $4,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,390.22 |
| Education | $132.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,500.17 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $1,736.53 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Janssen Pharmaceuticals, INC | $1,715.16 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| R-Pharm US LLC | $1,325.50 | 2020 | |
| Pbg Puerto Rico LLC | $1,248.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $973.25 | 2020-2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $946.44 | 2021-2025 | Lupron Depot, Venclexta |
| Genentech USA, INC. | $856.48 | 2021-2025 | Vabysmo, Polivy, Lunsumio |
| Amgen INC. | $853.57 | 2019-2025 | Lumakras, Xgeva, Kyprolis |
| Eli Lilly Export S.A. Puerto Rico Branch | $728.40 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $617.11 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $615.10 | 2021-2025 | |
| Genzyme Corporation | $559.32 | 2020-2025 | |
| Puma Biotechnology, INC. | $431.84 | 2020-2025 | |
| Eisai INC. | $357.09 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $323.47 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.64 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $245.83 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Gilead Sciences, INC. | $221.17 | 2022-2025 | Trodelvy |
| Seagen INC. | $210.07 | 2020-2023 | Adcetris |
| Bayer Puerto Rico INC. | $202.42 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Sobi, INC | $200.09 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $176.17 | 2024-2025 | Libtayo, Lynozyfic |
| Fennec Pharmaceuticals, INC. | $171.51 | 2024-2025 | Fyarro, Pedmark |
| Astellas Pharma US INC | $166.58 | 2021-2024 | Padcev |
| Alexion Pharmaceuticals, INC. | $152.53 | 2025 | Ultomiris |
| Taiho Oncology, INC. | $121.37 | 2024-2025 | |
| Beigene USA, INC. | $99.74 | 2022-2025 | Brukinsa |
| Verity Pharmaceuticals INC. | $96.62 | 2021-2024 | Trelstar |
| Springworks Therapeutics, INC. | $82.67 | 2025 | Ogsiveo |
| Exelixis INC. | $72.91 | 2022-2025 | Cabometyx |
| Tempus Ai, INC | $69.81 | 2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $66.32 | 2019-2025 | Onivyde |
| Tolmar, INC. | $63.93 | 2023-2025 | Eligard, Rubraca |
| Sun Pharmaceutical Industries INC. | $59.13 | 2025 | |
| Caris Mpi, INC. | $56.55 | 2025 | Mi Cancer Seek |
| Tolmar Pharmaceuticals, INC. | $48.80 | 2022 | |
| Stemline Therapeutics INC. | $46.50 | 2025 | Orserdu |
| Pharmaand Gmbh | $44.16 | 2025 | Rubraca |
| Genmab U.S., INC. | $44.13 | 2025 | Epkinly |
| Beone Medicines USA, INC. | $41.77 | 2025 | Brukinsa |
| Clovis Oncology, INC. | $39.51 | 2021 | |
| Array Biopharma INC | $34.94 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Pfizer Pharmaceuticals LLC | $31.20 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $30.38 | 2019 | |
| Kyowa Kirin, INC. | $25.00 | 2025 | |
| Pharmaessentia USA Corporation | $24.53 | 2023 | Besremi |
| Morphosys, US INC. | $24.53 | 2023 | Monjuvi |
| Glaxosmithkline, LLC. | $24.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.18 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.46 | 2021 | |
| Lilly USA, LLC | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Acaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.